Wells Fargo & Company Aprea Therapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 13, 2023	BUY	$0.32 - $15.2 $1,644 - $78,097	5,138 Added 3670.0%	5,278 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.71 - $13.6 $331 - $6,351	-467 Reduced 76.94%	140 $0
Q2 2022 Aug 12, 2022	BUY	$0.62 - $1.94 $316 - $991	511 Added 532.29%	607 $0
Q1 2022 May 16, 2022	BUY	$1.59 - $3.16 $1 - $3	1 Added 1.05%	96 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $5.58 $272 - $530	95 New	95 $0
Q2 2021 Aug 16, 2021	SELL	$4.05 - $5.5 $122,719 - $166,655	-30,301 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$4.73 - $8.15 $117,199 - $201,940	24,778 Added 448.63%	30,301 $155,000
Q4 2020 Feb 09, 2021	SELL	$4.92 - $30.67 $33,687 - $209,997	-6,847 Reduced 55.35%	5,523 $27,000
Q3 2020 Nov 05, 2020	BUY	$21.66 - $38.86 $16,266 - $29,183	751 Added 6.46%	12,370 $298,000
Q2 2020 Aug 13, 2020	BUY	$25.47 - $39.69 $118,333 - $184,399	4,646 Added 66.63%	11,619 $451,000
Q1 2020 May 14, 2020	BUY	$31.65 - $45.3 $220,695 - $315,876	6,973 New	6,973 $242,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,741
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.